These four startups get the first kick
18.08.2014
PrognosiX, ImagineCargo, Mobile 3D Scanner and Lucentx convinced the jury and received their first kick with CHF 10.000 of pre-seed funding. Before they compete in the second round for another another CHF 20.000 we give you a short first impression of our new rising stars.
![]() Peter Kauf from PrognosiX
|
![]() |
![]() Nick Blake from ImagineCargo
|
![]() |
![]() The team behind Mobile 3D Scanner
|
![]() |
![]() Alberto Schena and Rudolf Griss from Lucentix
|
![]() |
venture challenge Alumnus Peter Kauf is developing with his team from PrognosiX Sales Forecasting a new generation of sales forecasting tools. Their algorithms combine patterns in historic data with present and future information like weather or promotions and communicate their findings in a transparent way. Such, they support procurement managers with reliable forecasts and help to reduce food waste and stock-out.
Nick Blake and his co-founder Benjamin Duh from ImagineCargo are reducing the emissions impact of package delivery by creating a radical alternative to conventional integrator/express networks. How? By bike. Transportation is a significant contributor to negative external environmental and societal impacts, this is why ImagineCargo delivers the packages by bike-train-bike instead of trucks, planes and trucks again.
3D Mobile Scanner: Turning mobile phones into 3D scanners? This is what Amaël Delaunoy, Kalin Kolev, Petri Tanskanen and Marc Pollefeys will make possible. They are developing software technologies for real-time 3D modeling on mobile consumer devices. Amaël and his team provide an interactive approach to the acquisition process which runs entirely on a mobile device. Their scanner works through a device camera and will allow it to everyone to capture the world in 3D.
Rudolf Griss and Alberto Schena from Lucentix are working on in vitro diagnostics to measure precise concentrations of analytes in single drops of body fluids at the point of care. The measurement can be performed by the patient at home instead of at the hospital. The test only takes a few minutes and gives laboratory-quality results. The technology relies on a novel biosensor mechanism and is applicable to a wide range of biomarkers and drugs.